{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/cellulitis-acute/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"59d003f6-dd50-5136-b5c2-c2ea4e4b6f01","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field fa2b7611-ecc1-4390-9890-025d79444918 --><h2>Changes</h2><!-- end field fa2b7611-ecc1-4390-9890-025d79444918 -->","summary":null,"htmlStringContent":"<!-- begin item 56dfaf84-8d13-48c9-b654-a9ac6882d071 --><!-- begin field f343986d-006f-4c38-b7bb-f2a772327ebc --><p><strong>January 2021 </strong>— minor update. Contraindications and drug interactions for erythromycin have been updated in line with an MHRA drug safety update. </p><!-- end field f343986d-006f-4c38-b7bb-f2a772327ebc --><!-- end item 56dfaf84-8d13-48c9-b654-a9ac6882d071 -->","topic":{"id":"c0841d82-0a64-5b27-81dc-9a825d85f1bf","topicId":"6db61277-29ef-49cc-bad1-d0d78d0afc10","topicName":"Cellulitis - acute","slug":"cellulitis-acute","lastRevised":"Last revised in January 2021","chapters":[{"id":"84376fdb-da2b-561d-bb40-28b5b1a7e975","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"bdf35905-533d-5cb1-bd18-9c1575427a25","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"d6c8c4bd-9395-5840-83c7-67ddfeabdf85","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"59d003f6-dd50-5136-b5c2-c2ea4e4b6f01","slug":"changes","fullItemName":"Changes"},{"id":"f79ca51e-9432-56b1-95de-92ed6133be2b","slug":"update","fullItemName":"Update"}]},{"id":"05002b30-8200-5ccf-b9da-7c96acdb65bd","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fefb70b6-1d32-5e70-afc6-291fa40b3137","slug":"goals","fullItemName":"Goals"},{"id":"cf84220a-f381-5ca1-aa76-ffb99c4959f6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"aa32cbb7-29d6-58b6-bcde-7702767672ec","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7e039433-2afe-5980-93f0-c20c41976610","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d1411fdd-dc83-5f20-9fa4-ad67b69c195a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"ce40a600-51e8-5b3a-86c2-d127f03c16eb","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ff60c523-3d6f-5766-8508-98e8cdcf08f5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8e8cfe4a-13f2-573c-ab45-7231016746c4","slug":"definition","fullItemName":"Definition"},{"id":"2b7befe3-0fef-5d4e-b00d-bad6742fb93c","slug":"causes","fullItemName":"Causes"},{"id":"96971948-f52b-561c-84f8-8600f3eff2d4","slug":"prevalence","fullItemName":"Prevalence"},{"id":"4749dc8a-3f24-5e65-a0a3-5d7665ef3085","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"ad3d41f6-595b-505c-b020-918f0e086d3f","slug":"complications","fullItemName":"Complications"},{"id":"82ccb916-06d4-5b29-91e4-90005f3db942","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"7305e6df-9b2c-5584-9412-54564432e382","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8625eea6-53ec-5348-befa-a609ea64590f","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"273b1216-536e-59b4-8c39-547a97824ffa","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"68b86e3a-ee13-5ccd-9df0-a5c70c553251","fullItemName":"Management","slug":"management","subChapters":[{"id":"195394ca-067a-5cf3-bc4d-52a189d2cba6","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"4426193a-52c1-59b9-9222-77fb7169a3d1","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"78de19b8-8e80-551f-8112-456ce2e25bb0","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"73060223-dd90-59da-bae3-c706b5d24298","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"83f47301-e112-5f78-a79a-5c03a9de9537","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"b7240858-fbcc-5f20-8dcd-19f0b7221ac4","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"07828388-33ed-5e04-90b7-28a76fa26c6e","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"4600d0c1-4cd1-51ee-87a0-b660f0fa2165","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"0c0b7a3f-11e4-5b00-bd21-b66e49f9ad77","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"29987f8b-20b6-5c1f-8d23-183b415a04fb","slug":"analgesia","fullItemName":"Analgesia"}]},{"id":"4b09dc1a-8268-50d6-a164-227a73b3556e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"d49b86e1-77b2-58e6-82c0-ea0aa7ee74ed","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"fe910063-69df-5218-bb78-36f5863db2a1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"129f5233-2934-55ad-a561-4eb37861dc10","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"74d5b6b4-ef9d-5fc4-b41b-656b81a7ded8","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"44402335-ffeb-5e14-9e77-bb8278ef43d6","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"04d7d640-f586-53d9-ac59-804c10dd593d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c50af1ff-f157-5023-92b4-aa07b1c28d76","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d6c8c4bd-9395-5840-83c7-67ddfeabdf85","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"b71acebe-bc0d-5a8b-af43-163f15229c54","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 1cc6d296-8d86-4438-814a-298bab368678 --><h3>Previous changes</h3><!-- end field 1cc6d296-8d86-4438-814a-298bab368678 -->","summary":null,"htmlStringContent":"<!-- begin item f0bb6f3e-246f-4d1c-bad3-38e31164d6a7 --><!-- begin field 8cd27b61-70a2-496b-a95c-07a62914f47f --><p><strong>December 2019</strong> — minor update. Text amended to clarify antibiotic choices for children with a true penicillin allergy.</p><p><strong>October 2019</strong> — minor update. The topic has been updated to align with the National Institue for Health and Care Excellence (NICE) guideline <em>Cellulitis and erysipelas: antimicrobial prescribing</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">NICE, 2019a</a>].  </p><p><strong>April 2019</strong><strong> </strong>— reviewed. A literature search was conducted in March 2019 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. No major changes to the recommendations have been made. However, the topic has undergone minor restructuring, and a prescribing information section has been added for doxycycline, which is now recommended as the first-line treatment for a person with a penicillin allergy who is also taking a statin.</p><p><strong>December 2016 </strong>— minor update. The dose of clarithromycin for people with severe renal impairment has been clarified, in line with the manufacturer's Summary of Product Characteristics (SPC). </p><p><strong>August 2016 </strong>— minor update. Information on the use of antibiotic treatment for cellulitis in children with varicella has been added.</p><p><strong>July 2015 </strong>— minor update. The information on the concurrent use of clarithromycin with statins has been clarified.</p><p><strong>March to June 2015 </strong>— reviewed. A literature search was conducted in March 2015 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of this topic. No major changes to the recommendations have been made. However, the topic has undergone minor restructuring, and prescribing information sections for the recommended antibiotics have been added.</p><p><strong>September 2014 </strong>— minor update. Text inserted to include recommendations on the management of people with cellulitis and varicella.</p><p><strong>May 2014 </strong>— minor update. Minor correction to the basis for the recommendation on prescribing clarithromycin. Recommendations in prescribing information have been clarified and links amended.</p><p><strong>June 2013 </strong>— minor update. Text regarding the risk of pseudomembranous colitis with flucloxacillin has been amended.</p><p><strong>February 2013</strong> — minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>October 2012</strong> — minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>September 2012</strong> — revised. A literature search was conducted in November 2011 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. No major changes to clinical recommendations have been made.</p><p><strong>July 2011 </strong>— minor update. More exact paracetamol dosing for children has been introduced by the Medicines and Healthcare products Regulatory Agency (MHRA). Prescriptions have been updated to reflect the revised dosing. Issued in July 2011.</p><p><strong>May 2011</strong> — minor update. The 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>November 2008</strong> — minor update. Co-amoxiclav added as an antibiotic option for treatment of mild facial cellulitis that does not require admission, in line with Health Protection Agency (HPA) recommendations. Issued in January 2009.</p><p><strong>July to September 2008</strong> — converted from CKS guidance to CKS topic structure. The evidence base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. Recommendations and prescriptions on recurrent cellulitis have been removed, as they are now considered out of scope. Other than this, there have been no major changes to the recommendations.</p><p><strong>October 2006</strong> — minor update. Analgesia prescriptions updated because new doses of ibuprofen for children are recommended by the British National Formulary (BNF). Issued in October 2006.</p><p><strong>June 2005</strong> — written. Validated in September 2005 and issued in November 2005.</p><!-- end field 8cd27b61-70a2-496b-a95c-07a62914f47f --><!-- end item f0bb6f3e-246f-4d1c-bad3-38e31164d6a7 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}